Rafael Pharmaceuticals Inc. said FDA has granted an orphan drug designation to CPI-613, the company’s lead Altered Energy Metabolism Directed drug candidate, for the treatment of peripheral T-cell lymphoma.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe